<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575103</url>
  </required_header>
  <id_info>
    <org_study_id>A0001</org_study_id>
    <nct_id>NCT04575103</nct_id>
  </id_info>
  <brief_title>Monitoring of Arrhythmias in Patients Treated With Antipsychotics</brief_title>
  <acronym>MAPP</acronym>
  <official_title>Monitoring of Arrhythmias in Patients Treated With Antipsychotics - The MAPP II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordsjaellands Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antipsychotics may be associated to life-threatening arrhythmias and sudden cardiac death.&#xD;
      This is the fist study to estimated the arrhythmic burden using long-term monitoring by&#xD;
      implantable loop recorder in patients treated with antipsychotics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims and objectives To estimate frequency of potential malign arrhythmias and cardiovascular&#xD;
      outcome in a population with patients treated with antipsychotic drugs compared to healthy&#xD;
      controls.&#xD;
&#xD;
      Background Life expectancy is about 20 years shorter for patients with mental illness&#xD;
      compared to the general population. Increasing evidence suggest that antipsychotic drugs can&#xD;
      cause cardiac arrhythmias and hence sudden death. However, the evidence as well as the&#xD;
      incidence of rhythm disturbances in patients treated with antipsychotic drugs is insufficient&#xD;
      reported. Prolonged monitoring with external portable monitors is difficult for practical and&#xD;
      technical reasons. In addition, long-term consistent and structured timing of clinical visits&#xD;
      is often a challenge in this vulnerable patient group. In recent years, patients who have&#xD;
      been suspected of rarely occurring arrhythmias, have been offered long-term monitoring using&#xD;
      an 'implantable loop recorder' (ILR). However, no study has evaluated the arrhythmic burden&#xD;
      in patients treated with antipsychotic drugs using ILR.&#xD;
&#xD;
      Methods and materials The study is a national joint project between departments of psychiatry&#xD;
      and cardiology across Denmark. After written informed consent and a baseline evaluation&#xD;
      including echocardiography, ecg and biochemistry, an ILR will be implanted. During follow-up,&#xD;
      arrhythmias will be monitored at regular clinical visits. Cardiovascular endpoints will be&#xD;
      monitored using Danish national registries.&#xD;
&#xD;
      Expected outcome and perspectives The present study is the first to reveal arrhythmias among&#xD;
      patients treated with antipsychotics using consistent long-term monitoring. The results will&#xD;
      give valuable insights into possible mechanism of the observed early death and risk of sudden&#xD;
      death in patients treated with antipsychotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular arrhythmias</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Number of patients with ventricular arrhythmias detected on insertable loop recorder</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Supraventricular arrhythmias</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Number of patients with supraventricular arrhythmias including atrial fibrillation or flutter detected on insertable loop recorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bradycardia</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Number of patients with bradycardia (defined as resting rate lower than 40/min) detected on insertable loop recorder.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Long QT interval</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Number of patients with long QT interval on routine ECG or detected on insertable loop recorder defined as QTc &gt; 500 ms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pacemaker/ICD implantation.</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Number of patients who receives pacemaker/ICD implantation using questionnaire and national pace- and ICD register.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sudden cardiac death.</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Number of patients who experiences sudden cardiac death using national death and diagnosis register.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Number of patients who experiences cardiovascular mortality using national death and diagnosis register.</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Number of patients who experiences all-cause mortality using national death and diagnosis register.</description>
  </other_outcome>
  <other_outcome>
    <measure>Suicide or death caused by non-cardiac factors</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Number of patients who experiences suicide or death caused by non-cardiac factors using national death and diagnosis register.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of primary endpoint in controls</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Frequency of primary endpoint in controls detected on insertable loop recorder.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of primary endpoint related to specific psychiatric drugs / dose</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Frequency of primary endpoint related to specific psychiatric drugs / dose detected on insertable loop recorder</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of primary endpoint related to the presence of long QTc interval</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Frequency of primary endpoint related to the presence of long QTc interval detected on insertable loop recorder</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of primary endpoint in poor metabolizers compared to normal metabolizers</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Frequency of primary endpoint in poor metabolizers compared to normal metabolizers detected on insertable loop recorder</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of primary endpoint by genetic analysis</measure>
    <time_frame>2 years from insertion og loop recorder</time_frame>
    <description>Frequency of primary endpoint by genetic analysis detected on insertable loop recorder.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Death, Sudden, Cardiac</condition>
  <condition>Arrythmia</condition>
  <condition>Antipsychotics and Neuroleptics Toxicity</condition>
  <arm_group>
    <arm_group_label>Antipsychotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with antipsychotics as provided by their psychiatrist in order to treat disease best possible and in accordance with guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy controls, not treated with antipsychotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antipsychotic</intervention_name>
    <description>Antipsychotic treatment &gt;0.5 DDD</description>
    <arm_group_label>Antipsychotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with SMI defined according to ICD-10 as:&#xD;
&#xD;
               -  F20.0-F20.9 schizophrenia&#xD;
&#xD;
               -  F22.0-F22.9 paranoid psychosis&#xD;
&#xD;
               -  F25.0-F25.9 schizo-affective psychosis&#xD;
&#xD;
               -  F28 other non-organic psychosis&#xD;
&#xD;
               -  F29 non-organic psychosis unspecified&#xD;
&#xD;
               -  F31.0-F31.9 bipolar affective disorder.&#xD;
&#xD;
          -  Patients treated with or initiating antipsychotics with ≥ 0.5 daily defined dosage&#xD;
&#xD;
          -  &gt;18 years old and &lt;50 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not capable to understand the aim of the study as judged by investigator.&#xD;
&#xD;
          -  Current in treatment with methadone.&#xD;
&#xD;
          -  Left ventricular hypertrophy (echocardiographic septal thickness ≥1.3 cm for women and&#xD;
             ≥1.4 cm for men, or LVM/BSA ≥109 g/m2 for women or ≥132 g/m2 for men).&#xD;
&#xD;
          -  Heart failure (echocardiographic LVEF &lt;35%).&#xD;
&#xD;
          -  Ischemic heart disease (patient reported coronary bypass grafting or percutaneous&#xD;
             coronary intervention.&#xD;
&#xD;
          -  Congenital cardiovascular disease (patient reported).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Casper Bang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Bispebjerg and Frederiksberg Hospital, Copenhagen University, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Casper N Bang, MD, PhD</last_name>
    <phone>+4538635000</phone>
    <email>casper.niels.furbo.bang@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gunnar H Gislason, MD, PhD</last_name>
    <email>gunnar.gislason@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry, Region of Southern Denmark</name>
      <address>
        <city>Aabenraa</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mikkel Højlund, MD</last_name>
      <email>mikkel.hojlund2@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology, Aalborg Universitetshospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob M Larsen, MD</last_name>
      <email>jaml@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatry, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René E Nielsen, MD, PhD</last_name>
      <email>ren@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital, Skejby, Department of Cardiology</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik K Jensen, DMSc, PhD</last_name>
      <email>hkjensen@clin.au.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Aarhus University</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ole Mors, MD, PhD</last_name>
      <email>ole.mors@clin.au.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital, Department of Cardiology</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Søren Højberg, MD, PhD</last_name>
      <email>Soeren.Hoejberg@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copenhagen Center of Psychiatry (Rigshospitalet)</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anders Fink-Jensen, MD, DMSc</last_name>
      <email>anders.fink-jensen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mental Health Center Amager</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Nordgaard, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <email>julie.nordgaard.frederiksen@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Department of Cardiology</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Berit Philbert, MD, PhD</last_name>
      <email>berit.thornvig.philbert@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mental Health Center Frederiksberg</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Runa I Munker, MD</last_name>
      <email>runa.munkner@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte-Herlev Hospital, Department of Cardiology</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tommi B Lindhardt, MD, PhD</last_name>
      <email>Tommi.bo.lindhardt@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mental Health Center Glostrup</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Casper B Westergaard, MD</last_name>
    </contact>
    <contact_backup>
      <email>casper.buchardt.westergaard@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mental Health Center Copenhagen</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Merete Nordentoft, MD, DMSc</last_name>
      <email>merete.nordentoft@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Zealand Hospital, Department of Cardiology</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael D Jacobsen, MD</last_name>
      <email>michael.dilou.jacobsen.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Zealand Hospital, Department of Psychiatry</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotte Hechmann, MD</last_name>
      <email>charlotte.hechmann@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital, Department of Cardiology</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stine O Poulsen, MD</last_name>
      <email>Stine.Odgaard.Poulsen1@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital, Department of Cardiology</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas M Mechior, MD, PhD</last_name>
      <email>tmme@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatric Research Unit, Region of Zealand</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erik Simonsen, MD, PhD</last_name>
      <email>es@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Bispebjerg and Frederiksberg</investigator_affiliation>
    <investigator_full_name>Casper N. Bang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

